Lecithinized superoxide dismutase

Drug Profile

Lecithinized superoxide dismutase

Alternative Names: Superoxide dismutase-lecithinized

Latest Information Update: 14 Nov 2006

Price : $50

At a glance

  • Originator Seikagaku Corporation
  • Developer Asahi Glass; Seikagaku Corporation
  • Class Anti-ischaemics
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute lung injury; HIV infections; Myocardial ischaemia

Most Recent Events

  • 06 May 2003 Preclinical trials in HIV infections treatment in Japan (unspecified route)
  • 06 May 2003 Preclinical trials in Myocardial ischaemia in Japan (unspecified route)
  • 22 Nov 2002 No development reported - Phase-II for Acute lung injury in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top